Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RadProtect (META Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Meta
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
OBM-A01 (RadProtect) is a sustained-release, amifostine-based formulation developed by Original BioMedicals for the prevention and treatment of radiation injury, including acute radiation syndrome (ARS). It utilizes a proprietary chelating-complex micelle and triggered-release technology, where amifostine is encapsulated in polyethylene glycol-b-poly(glutamic acid) micelles and stabilized by iron (II) ions. This formulation significantly extends the half-life of amifostine, providing prolonged cytoprotection and free-radical scavenging activity to protect healthy tissues and organs (such as bone marrow and salivary glands) from ionizing radiation. OBM-A01 is also being explored as an ultrasound contrast agent.
- Brand names
- RadProtect
02
Targets
ALPL (Tissue-nonspecific alkaline phosphatase)DNA
Beyond the preview
Go deeper on RadProtect (META Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RadProtect (META Pharmaceuticals).